Response Rate of Bevacizumab and FOLFOXIRI with pegfilgrastim in RAS-mutant type unresectable metastatic colorectal cancer.

ABSTRACT: Interventions: Biweekly FOLFOXIRI+Bevacizumab +Pegfilgrastim Bevacizumab 5mg/kg/ q2w Oxaliplatin 85mg/m2/ q2w Irinotecan 165mg/m2/ q2w l-LV 200mg/m2/ q2w 5FU-infusional 3,200mg/m2/ q2w Pegfilgrastim 3.6mg / q2w Primary outcome(s): ORR: overall response rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2633492 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR